Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study

This publication has 23 references indexed in Scilit:

• Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation
  Blood, 2006
• Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus
  The Journal of Infectious Diseases, 2003
• Phase I Safety and Pharmacokinetic Trials of 1263W94, a Novel Oral Anti-Human Cytomegalovirus Agent, in Healthy and Human Immunodeficiency Virus-Infected Subjects
  Antimicrobial Agents and Chemotherapy, 2003
• Phase I Dose Escalation Trial Evaluating the Pharmacokinetics, Anti-Human Cytomegalovirus (HCMV) Activity, and Safety of 1263W94 in Human Immunodeficiency Virus-Infected Men with Asymptomatic HCMV Shedding
  Antimicrobial Agents and Chemotherapy, 2002
• Potent and Selective Inhibition of Human Cytomegalovirus Replication by 1263W94, a Benzimidazole l -Riboside with a Unique Mode of Action
  Antimicrobial Agents and Chemotherapy, 2002
• Definitions of Cytomegalovirus Infection and Disease in Transplant Recipients
  Clinical Infectious Diseases, 2002
• Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation
  Blood, 2002
• Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients
  Blood, 2001
• PLASMA POLYMERASE CHAIN REACTION FOR CYTOMEGALOVIRUS DNA AFTER ALLOGENEIC MARROW TRANSPLANTATION
  Transplantation, 1997
• Analysis Of The Ul97 Phosphotransferase Coding Sequence In Clinical Cytomegalovirus Isolates And Identification Of Mutations Conferring Ganciclovir Resistance
  The Journal of Infectious Diseases, 1995